

In the Claims

1-34. (canceled)

35. (currently amended) An isolated polypeptide consisting of:

- a) amino acids 94-124 (SEQ ID NO: 6) of human OX40 ligand (OX40L)OX40L;
- b) amino acids 94-124 (SEQ ID NO: 6) wherein one or more amino acids have been deleted and said polypeptide binds to the OX40 receptor (OX40R);
- c) ~~amino acids 107-111 (SEQ ID NO: 13) of human OX40L;~~
- d) ~~—~~a peptide sequence of human OX40L having of between 5 and 10 amino acids that binds to OX40R;
- e)d) ~~a peptide having the sequence corresponding to amino acids 107-116 (SEQ NO ID: 8) or 107-111 (SEQ ID NO: 13) of human OX40L;~~
- f)e) an active mutant of a), b), c), d) or e) a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R;
- g)f) a fusion polypeptide or peptide comprising a), b), c), d), e) or f) and an amino acid sequence belonging to a protein sequence other than human OX40L (SEQ ID NO: 1) fused to:
  - i) a peptide consisting of amino acids 94-124 (SEQ ID NO: 6) of human OX40L;
  - ii) a peptide consisting of amino acids 94-124 (SEQ ID NO: 6) wherein one or more amino acids have been deleted and said fusion polypeptide binds OX40R;
  - iii) a peptide sequence of human OX40L between 5 and 10 amino acids that binds to OX40R;
  - iv) a peptide consisting of amino acids 107-116 (SEQ NO ID: 8) or 107-111 (SEQ ID NO: 13) of human OX40L; or

h)g) ~~an active fraction, precursor, salt, or derivative of a), b), c), d), e), f) or g)~~  
derivative of a), b), c), d), e) or f).

36. (previously presented) The isolated polypeptide according to claim 35, wherein said fusion polypeptide or peptide comprises the amino acid sequence belonging to one or more of the following protein sequences: membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.

37. (previously presented) The isolated polypeptide according to claim 35, further comprising a molecule selected from the group consisting of radioactive labels, biotin, fluorescent labels, cytotoxic agents, and drug delivery agents.

38. (previously presented) The isolated polypeptide according to claim 35, further comprising a solid support.

39. (previously presented) An isolated peptide, peptide mimetic, or a non-peptide mimetic designed on the sequence, the structure or the sequence and structure of an amino acid sequence corresponding to 107-116 (SEQ NO ID: 8) or 107-111 (SEQ ID NO: 13) of human OX40L.

40-46. (canceled)

47. (previously presented) A composition comprising a polypeptide according to claim 35 and a pharmaceutically acceptable carrier, excipient, stabilizer, diluent, or combination thereof.

48-50. (canceled)

51. (withdrawn) A method of treating a disease or condition comprising the administration of a composition according to claim 47 to an individual in need of treatment.

52-55 (canceled).

56. (withdrawn) A method of antagonizing the activity of OX40L comprising contacting a composition according to claim 47 with a composition containing OX40R.